AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $41,200 | -37.5% | 4,000 | 0.0% | 0.00% | -42.9% |
Q2 2023 | $65,920 | +79.9% | 4,000 | 0.0% | 0.01% | +75.0% |
Q1 2023 | $36,640 | +27.9% | 4,000 | 0.0% | 0.00% | +33.3% |
Q4 2022 | $28,640 | +43.2% | 4,000 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $20,000 | +100.0% | 4,000 | 0.0% | 0.00% | +50.0% |
Q2 2022 | $10,000 | -63.0% | 4,000 | 0.0% | 0.00% | -50.0% |
Q1 2022 | $27,000 | -15.6% | 4,000 | 0.0% | 0.00% | -20.0% |
Q4 2021 | $32,000 | -17.9% | 4,000 | 0.0% | 0.01% | -37.5% |
Q3 2021 | $39,000 | +44.4% | 4,000 | 0.0% | 0.01% | +33.3% |
Q2 2021 | $27,000 | -25.0% | 4,000 | 0.0% | 0.01% | -45.5% |
Q1 2021 | $36,000 | +33.3% | 4,000 | 0.0% | 0.01% | +22.2% |
Q4 2020 | $27,000 | +35.0% | 4,000 | 0.0% | 0.01% | +12.5% |
Q3 2020 | $20,000 | -37.5% | 4,000 | 0.0% | 0.01% | -46.7% |
Q2 2020 | $32,000 | 0.0% | 4,000 | 0.0% | 0.02% | -25.0% |
Q1 2020 | $32,000 | +6.7% | 4,000 | 0.0% | 0.02% | +17.6% |
Q4 2019 | $30,000 | +76.5% | 4,000 | 0.0% | 0.02% | +54.5% |
Q3 2019 | $17,000 | – | 4,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |